About this trial
It is known that deep neuromuscular block improves surgical conditions, especially during laparoscopic abdominal surgery. Based on this, in the Perioperative Neuromuscular Blockade Management guide published by the ESAIC association in 2022, it is recommended to deepen the level of neuromuscular blockade in cases where surgical conditions need to be improved. Sugammadex should be used to quickly and reliably reverse deep neuromuscular blockade. TOFScan, a 3-dimensional acceleromyograph for neuromuscular monitoring, has become widely used in recent years. With this monitor, it has been shown that in addition to the classical train-of-four ratio (cTOFR), the modified train-of-four ratio (mTOFR) can be used during the spontaneous recovery of nondepolarizing neuromuscular blockade. In a study conducted by Schmartz et al. in 2021, it was shown that mTOFR, which is the ratio of T4 to the reference stimulus, was compiled later than cTOFR. Therefore, it is suggested that the mTOFR value is a better determinant for safe extubation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 18 - 65 (not including 65)
BMI: 18.5-24.9
Disqualifiers
Liver and kidney disease
Non-consenting
Emergency surgeries
Muscle disease
Trial population
Surgeries where neuromuscular blockers are used under general anesthesia
Trial design
Cohort
Prospective
Treatments tested in this trial
TOFscan monitoring
Deviceobservation and data recording
Treatment groups
Trial outcomes
Primary outcomes
time
Comparison of classical and modified TOF rates to reach 90% and above
Secondary outcomes
time
Comparison of the time to reach 100% for classical and modified TOF rates
Sponsors and contacts
Click on the lead sponsor to view all of their trials.